CRVS vs. YS, HOOK, TPST, CNTB, VTVT, CUE, SPRO, ASMB, MRNS, and CARM
Should you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include YS Biopharma (YS), Hookipa Pharma (HOOK), Tempest Therapeutics (TPST), Connect Biopharma (CNTB), vTv Therapeutics (VTVT), Cue Biopharma (CUE), Spero Therapeutics (SPRO), Assembly Biosciences (ASMB), Marinus Pharmaceuticals (MRNS), and Carisma Therapeutics (CARM). These companies are all part of the "pharmaceutical preparations" industry.
YS Biopharma (NASDAQ:YS) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, analyst recommendations, risk and dividends.
Corvus Pharmaceuticals received 284 more outperform votes than YS Biopharma when rated by MarketBeat users. However, 100.00% of users gave YS Biopharma an outperform vote while only 62.23% of users gave Corvus Pharmaceuticals an outperform vote.
YS Biopharma presently has a consensus target price of $5.25, indicating a potential upside of 624.54%. Corvus Pharmaceuticals has a consensus target price of $6.63, indicating a potential upside of 324.68%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe YS Biopharma is more favorable than Corvus Pharmaceuticals.
YS Biopharma has higher revenue and earnings than Corvus Pharmaceuticals.
Corvus Pharmaceuticals' return on equity of 0.00% beat YS Biopharma's return on equity.
52.6% of YS Biopharma shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 31.3% of Corvus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
YS Biopharma has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.
In the previous week, YS Biopharma had 5 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 7 mentions for YS Biopharma and 2 mentions for Corvus Pharmaceuticals. YS Biopharma's average media sentiment score of 0.00 beat Corvus Pharmaceuticals' score of -0.17 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.
Summary
YS Biopharma beats Corvus Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
Get Corvus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corvus Pharmaceuticals Competitors List
Related Companies and Tools
